The estimated Net Worth of Thomas A. West is at least $13.9 Million dollars as of 17 March 2020. Mr. West owns over 19,035 units of Intersect ENT Inc stock worth over $6,689,774 and over the last 10 years he sold XENT stock worth over $0. In addition, he makes $7,206,100 as President, Chief Executive Officer, and Director at Intersect ENT Inc.
Thomas has made over 3 trades of the Intersect ENT Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 19,035 units of XENT stock worth $161,417 on 17 March 2020.
The largest trade he's ever made was buying 19,035 units of Intersect ENT Inc stock on 17 March 2020 worth over $161,417. On average, Thomas trades about 933 units every 60 days since 2014. As of 17 March 2020 he still owns at least 236,890 units of Intersect ENT Inc stock.
You can see the complete history of Mr. West stock trades at the bottom of the page.
Thomas A. West serves as President, Chief Executive Officer, Director of the Company., effective July 22, 2019. He has served as our President and Chief Executive Officer and as a member of our Board of Directors since July 2019. Previously, he served as Division President, Diagnostics Solutions at Hologic, Inc., a medical technology company, from 2014 to 2019, where he was responsible for managing Hologic’s domestic and international diagnostics solutions business. In 2017, Mr. West assumed the additional role of general manager of Hologic’s full portfolio of businesses, Diagnostics, Breast Health, Surgical and Aesthetics, in Latin America. Prior to Hologic, Mr. West held various roles of increasing responsibility over a 23-year tenure at Johnson & Johnson, a medical device and pharmaceutical company. Most recently he served as Worldwide Vice President of Strategy and Business Development for Johnson & Johnson’s Diabetes Solutions Companies from 2009 to 2014. He also served as President of LifeScan North America from 2006 to 2009 and as President of LifeScan Europe, Middle East and Africa (EMEA), a diagnostic systems manufacturer, from 2005 to 2006. Mr. West has served on the Board of Directors of AdvaMed, the medical technology trade association since 2019. He served on the Board of AdvaMed Dx, the diagnostic trade association from 2014 to 2019. He has also served on the Board of Directors of BioCom, the pharmaceutical and medical technology trade association of the state of California since 2014.
As the President, Chief Executive Officer, and Director of Intersect ENT Inc, the total compensation of Thomas West at Intersect ENT Inc is $7,206,100. There are no executives at Intersect ENT Inc getting paid more.
Thomas West is 56, he's been the President, Chief Executive Officer, and Director of Intersect ENT Inc since 2019. There are 12 older and no younger executives at Intersect ENT Inc. The oldest executive at Intersect ENT Inc is Frederic Moll, 68, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA, CA, 95050.
Over the last 10 years, insiders at Intersect ENT Inc have traded over $22,664,783 worth of Intersect ENT Inc stock and bought 58,846 units worth $713,631 . The most active insiders traders include Rick D Anderson, Lisa D Earnhardt, and W Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of $344,556. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth $9,000.
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
Intersect ENT Inc executives and other stock owners filed with the SEC include: